AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35507481
Drug: ZF2001 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZF2001 vaccine (25-μg doses, 3 doses, 30 days apart)
Trial: 35604960
Drug: Topical 10
RxNorm normalized name: urea topical 10% topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 10 mg Z-endoxifen
Trial: 35604960
Drug: Topical 20
RxNorm normalized name: urea topical 20% topical foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 20 mg Z-endoxifen
Trial: 33993571
Drug: alfentanil 14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfentanil 14 mcg kg−1
Trial: 33993571
Drug: rocuronium 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rocuronium 0.3 mg kg−1
Trial: 33993571
Drug: propofol 2
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propofol 2 mg kg−1
Trial: 34655071
Drug: Intracavernosal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavernosal injection of autologous mesenchymal stem cells (50-60 ×106 cells)
Trial: 34655071
Drug: Intracavernosal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavernosal injection of autologous mesenchymal stem cells
Trial: 36421007
Drug: Immunotherapy added
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immunotherapy added to chemotherapy
Trial: 33407345
Drug: Spinal manipulative
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal manipulative therapy at the most pain-sensitive segment
Trial: 33407345
Drug: Spinal manipulative
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal manipulative therapy at the stiffest segment
Trial: 32379165
Drug: Topical almond
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical almond oil (6.5 cc applied daily for 7 days)
Trial: 32379165
Drug: Placebo (liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (liquid paraffin, 6.5 cc applied daily for 7 days)
Trial: 32379165
Drug: Topical almond
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical almond oil
Trial: 32319999
Drug: NT‐proBNP‐guided treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT‐proBNP‐guided treatment (goal to suppress NT‐proBNP concentrations to <1000 pg/mL)
Trial: 32319999
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of β‐blockers
Trial: 32319999
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of ACE inhibitors
Trial: 32319999
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of ARBs
Trial: 32319999
Drug: Increasing doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing doses of mineralocorticoid antagonists
Trial: 35947884
Drug: Open-label placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label placebo treatment for three weeks
Trial: 35947884
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no open-label placebo treatment)
Trial: 33788987
Drug: Adverse events
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse events from LED-RL treatment
Trial: 34151132
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months of adjuvant afatinib (30 mg by mouth daily)
Trial: 34151132
Drug: 2 years
RxNorm normalized name: Childrens Panadol 5 - 12 Years
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 years of adjuvant afatinib (30 mg by mouth daily)
Trial: 34156697
Drug: Olfactory rehabilitation
RxNorm normalized name: BOS TAURUS OLFACTORY BULB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olfactory rehabilitation plus daily oral supplement with Palmitoylethanolamide (PEA) and Luteolin
Trial: 35850742
Drug: Daily Contact
RxNorm normalized name: CONTACT LENS DAILY CLEANER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Contact Testing (DCT) using Lateral Flow Test (LFT) and two Polymerase Chain Reaction (PCR) tests for 7 days
Trial: 33127945
Drug: 75/650 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75/650 mg tramadol with paracetamol every 8 hours
Trial: 33127945
Drug: 37.5/325 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 37.5/325 mg tramadol with paracetamol every 8 hours
Trial: 34156898
Drug: Romyelocel-L infusion
RxNorm normalized name: Romyelocel-L
DrugBank: Romyelocel-L (DB19268)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Romyelocel-L infusion on d9 with granulocyte colony-stimulating factor (G-CSF) starting daily d14
Trial: 34156898
Drug: G-CSF daily
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF daily alone on d14 (control)
Trial: 34459905
Drug: Mobile app
RxNorm normalized name: Mahana IBS CBT Mobile Application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile app for pediatric drug preparation (n = 74)
Trial: 34459905
Drug: Conventional drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drug preparation methods (n = 76)
Trial: 36942789
Drug: Intravenous hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous hydrocortisone
Trial: 34233965
Drug: Nangibotide (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nangibotide (two doses)
Trial: 33460048
Drug: Immediate-release methylphenidate
RxNorm normalized name: methylphenidate Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release methylphenidate
Trial: 34614447
Drug: SEP‐4199 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEP‐4199 200 mg/d
Trial: 34614447
Drug: SEP‐4199 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEP‐4199 400 mg/d
Trial: 32270926
Drug: Fenebrutinib 200
RxNorm normalized name: Fenebrutinib
DrugBank: Fenebrutinib (DB14785)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenebrutinib 200 mg twice daily
Trial: 34750553
Drug: Fenebrutinib 150
RxNorm normalized name: Fenebrutinib
DrugBank: Fenebrutinib (DB14785)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenebrutinib 150 mg daily
Trial: 34750553
Drug: Fenebrutinib 50
RxNorm normalized name: Fenebrutinib
DrugBank: Fenebrutinib (DB14785)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenebrutinib 50 mg daily
Trial: 34750553
Drug: Fenebrutinib (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenebrutinib (all doses)
Trial: 34750553
Drug: Fenebrutinib 150
RxNorm normalized name: Fenebrutinib
DrugBank: Fenebrutinib (DB14785)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenebrutinib 150 mg daily and 200 mg twice daily
Trial: 34561715
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of estradiol (E2) after observation of a gestational sac and heartbeat (study group)
Trial: 34561715
Drug: Continued estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continued estradiol (E2) administration until week 12 of gestational age (control group)
Trial: 34561715
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups continued progesterone-in-oil administration until week 12 of gestational age
Trial: 33604969
Drug: Preemptive clobetasol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive clobetasol 0.05% cream applied twice per day for 8 weeks
Trial: 33604969
Drug: Reactive clobetasol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reactive clobetasol 0.05% cream applied twice per day for 8 weeks
Trial: 34289481
Drug: Prosody Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prosody Treatment Program (1 hour, once per week for 3 months)
Trial: 32334478
Drug: 7-day regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 7-day regimen of 500 mg amoxicillin four times daily, 500 mg tetracycline four times daily, and 20 mg omeprazole twice daily
Trial: 32334478
Drug: 14-day regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 14-day regimen of 500 mg amoxicillin four times daily, 500 mg tetracycline four times daily, and 20 mg omeprazole twice daily
Trial: 35685075
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy based on applied behavior analysis (ABA) (control group)
Trial: 32621262
Drug: Preventive Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive Oral Care Program (POCP) alone
Trial: 32621262
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (PBMT) associated with POCP
Trial: 34315495
Drug: Lipoprotein(a) levels
RxNorm normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipoprotein(a) levels > 28.72 mg/dL (Q4)
Trial: 34315495
Drug: Lipoprotein(a) levels
RxNorm normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipoprotein(a) levels > 28.72 mg/dL (Q4) among men
Trial: 34315495
Drug: Lipoprotein(a) levels
RxNorm normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipoprotein(a) levels > 28.72 mg/dL (Q4) among individuals age > 60 years
Trial: 32964537
Drug: Serelaxin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serelaxin treatment
Trial: 37461117
Drug: Multimodal group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal group (virtual care at home including exercise, nutrition counselling, medication consultation)
Trial: 37461117
Drug: Socialization group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Socialization group (once-weekly phone calls)
Trial: 32998148
Drug: Fingerroot (Boesenbergia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingerroot (Boesenbergia rotunda) extract (350 mg extract powder, 3 times daily for 4 weeks)
Trial: 32352903
Drug: Serratus anterior
RxNorm normalized name: Fucus serratus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serratus anterior plane (SAP) block with 20 mL of 0.2% ropivacaine and 1 μg/mL fentanyl as bolus followed by infusion at 8 mL/h
Trial: 32352903
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received saline for both bolus and infusion
Trial: 34702956
Drug: Linoleic acid
RxNorm normalized name: Linoleic acid
DrugBank: Linoleic acid (DB14104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linoleic acid treatment
Trial: 36185291
Drug: Integrated yoga
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated yoga therapy intervention during chemotherapy
Trial: 36185291
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care during chemotherapy
Trial: 33827835
Drug: Perioperative virtual
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative virtual reality‐based stress reduction exercises twice daily
Trial: 33827835
Drug: Listening to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Listening to classical music twice daily
Trial: 34956580
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous infusion of quick‐acting insulin analogues
Trial: 34898333
Drug: Concurrent validity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent validity assessment
Trial: 32337796
Drug: Access to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Access to therapy or social supports
Trial: 34669096
Drug: In-person consultation
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In-person consultation offered to women traced by the Genetic Unit (G.U.)
Trial: 33555030
Drug: Daratumumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab monotherapy (after Cycle 8)
Trial: 34915741
Drug: UGN-101 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UGN-101 (6 once-weekly instillations via retrograde catheter)
Trial: 32732703
Drug: Implementation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implementation of evidence-based medicine
Trial: 36244331
Drug: Mirabegron 50
RxNorm normalized name: mirabegron 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron 50 mg + Tamsulosin 0.4 mg once daily
Trial: 34631986
Drug: Symptom Management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom Management Intervention (SMI) with tailored weekly group sessions and mobile health application
Trial: 37052334
Drug: Buspirone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (10 mg orally, three times per day)
Trial: 33206270
Drug: Pregabalin with
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin with antioxidants therapy for 8 weeks
Trial: 32769505
Drug: Active nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active nerve block with 20 ml of 0.375% levobupivacaine and clonidine 0.5 μg/kg
Trial: 33008934
Drug: Lebrikizumab 250
RxNorm normalized name: Lebrikizumab 250 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [EBGLYSS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lebrikizumab 250 mg subcutaneously every 4 weeks
Trial: 33008934
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Lebrikizumab with pirfenidone)
Trial: 32111310
Drug: Conventional cage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional cage (CC) housing system
Trial: 33233227
Drug: Yacon syrup
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yacon syrup (40 g)
Trial: 33233227
Drug: Placebo (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (40 g)
Trial: 33639349
Drug: 20% biochar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% biochar litter treatment
Trial: 34706556
Drug: MEDI5884 (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI5884 (50, 100, 200, 350, or 500 mg SC)
Trial: 34706556
Drug: MEDI5884 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI5884 (500 mg SC)
Trial: 35681264
Drug: Single immune
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single immune checkpoint inhibitor (ICI)
Trial: 35681264
Drug: Single ICI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ICI plus chemotherapy
Trial: 34155332
Drug: 90 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg/day of baclofen
Trial: 32676976
Drug: Keguan-1 19.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Keguan-1 19.4 g twice daily plus control therapy (alpha interferon inhalation, 50 µg twice daily; and lopinavir/ritonavir, 400 and 100 mg twice daily)
Trial: 32676976
Drug: Control therapy
RxNorm normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control therapy (alpha interferon inhalation, 50 µg twice daily; and lopinavir/ritonavir, 400 and 100 mg twice daily)
Trial: 33757646
Drug: Renin–angiotensin–aldosterone system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renin–angiotensin–aldosterone system blockers
Trial: 34107828
Drug: One IPL
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One IPL treatment followed by three diode laser treatments
Trial: 34107828
Drug: Two IPL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two IPL treatments followed by three diode laser treatments
Trial: 34107828
Drug: Three IPL
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three IPL treatments followed by three diode laser treatments
Trial: 36339420
Drug: 1, 2,
RxNorm normalized name: Pneumococcal 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1, 2, 4, 8, or 12 µg/day CG beta plus rFSH
Trial: 36339420
Drug: CG beta
RxNorm normalized name: CG-200745
DrugBank: CG-200745 (DB12259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CG beta (highest dose group)
Trial: 32374623
Drug: NUC-1031 (725
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUC-1031 (725 mg/m2)/cisplatin (25 mg/m2)
Trial: 32374623
Drug: gemcitabine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine (1000 mg/m2)/cisplatin (25 mg/m2)
Trial: 32316391
Drug: Nucleotide-depleted mycoprotein
RxNorm normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleotide-depleted mycoprotein (L-NU)
Trial: 32316391
Drug: Both interventions
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both interventions (H-NU and L-NU)
Trial: 35972834
Drug: Cream with
RxNorm normalized name: CREAM WITH APPLICATOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream with glucocorticosteroid and fusidic acid
Trial: 35972834
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream with fusidic acid
Trial: 34062140
Drug: Voclosporin (23.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voclosporin (23.7 mg twice daily and 39.5 mg twice daily)
Trial: 32811741
Drug: Johrei treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Johrei treatment
Trial: 34388360
Drug: BI 695501
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 695501 (40 mg/0.8 mL formulation)
Trial: 34388360
Drug: Adalimumab reference
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab reference product (40 mg/0.4 mL or 40 mg/0.8 mL)
Trial: 35338469
Drug: Upacicalcet 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upacicalcet 0.01 mg
Trial: 35338469
Drug: Upacicalcet 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upacicalcet 0.1 mg
Trial: 35338469
Drug: Upacicalcet 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upacicalcet 1.0 mg
Trial: 35338469
Drug: Upacicalcet 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upacicalcet 2.5 mg
Trial: 35718502
Drug: Placebo (Jingfang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Jingfang Granules simulation agent)
Trial: 32048918
Drug: Trigger point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trigger point dry needling (TDN) combined with manual therapy (MT) and exercise (Ex)
Trial: 32048918
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy (MT) and exercise (Ex)
Trial: 34252914
Drug: Placebo-administered agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-administered agent (subcutaneous, endovenous, or oral)
Trial: 34252914
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of eptinezumab (anti-calcitonin gene-related peptide monoclonal antibody)
Trial: 34252914
Drug: Oral topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral topiramate
Trial: 34252914
Drug: Subcutaneous monoclonal
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous monoclonal
Trial: 34252914
Drug: Multiple head
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple head injections (botulinum toxin)
Trial: 33065733
Drug: Total opioid
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total opioid exposure increase (per mg/kg/d)
Trial: 33065733
Drug: Pain medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain medication or sedative administered in the previous 4 hours
Trial: 33065733
Drug: No progressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No progressive physical therapy or ambulation schedule
Trial: 35718625
Drug: Programmed intermittent
RxNorm normalized name: Program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programmed intermittent bolus infusion (PIBI)
Trial: 32223116
Drug: Oral anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulation alone